Further studies are needed, involving a larger number of subjects in a longer follow up period, to determine more precisely the effect of intravitreal and systemic erythropoietin and its concentration in diabetic retinopathy, in order to find new possibilities for better treatment and better quality of life of patients with diabetic retinopathy. Here, EPO is linked to diabetic retinopathy.